https://www.selleckchem.com/pr....oducts/hth-01-015.ht
Results were obtained for 1952 PSP and 728 non-PSP patients. PSP patients demonstrated better adherence to ADA than non-PSP patients, including higher PDC and persistence (all p 0.001). PSP patients were 13% less likely to initiate opioids and 26% less likely to have at least 2 fills than non-PSP patients, and they had fewer days of opioid supply (all p 0.01). This study supports the benefit of PSPs and suggests that the ADA PSP is associated with improved adherence and potentially lower opioid use. This study supports the
Like
Comment
Share
